DK0399666T3 - Fusionsproteiner indeholdende N-terminalfragmenter af human serumalbumin - Google Patents

Fusionsproteiner indeholdende N-terminalfragmenter af human serumalbumin

Info

Publication number
DK0399666T3
DK0399666T3 DK90304575.5T DK90304575T DK0399666T3 DK 0399666 T3 DK0399666 T3 DK 0399666T3 DK 90304575 T DK90304575 T DK 90304575T DK 0399666 T3 DK0399666 T3 DK 0399666T3
Authority
DK
Denmark
Prior art keywords
fusion proteins
serum albumin
human serum
proteins containing
terminal fragments
Prior art date
Application number
DK90304575.5T
Other languages
Danish (da)
English (en)
Inventor
David James Ballance
Original Assignee
Delta Biotechnology Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Delta Biotechnology Ltd filed Critical Delta Biotechnology Ltd
Application granted granted Critical
Publication of DK0399666T3 publication Critical patent/DK0399666T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DK90304575.5T 1989-04-29 1990-04-26 Fusionsproteiner indeholdende N-terminalfragmenter af human serumalbumin DK0399666T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB898909919A GB8909919D0 (en) 1989-04-29 1989-04-29 Small polypeptides

Publications (1)

Publication Number Publication Date
DK0399666T3 true DK0399666T3 (da) 1993-08-30

Family

ID=10656003

Family Applications (1)

Application Number Title Priority Date Filing Date
DK90304575.5T DK0399666T3 (da) 1989-04-29 1990-04-26 Fusionsproteiner indeholdende N-terminalfragmenter af human serumalbumin

Country Status (7)

Country Link
EP (2) EP0399666B1 (de)
AT (1) ATE92107T1 (de)
DE (1) DE69002395T2 (de)
DK (1) DK0399666T3 (de)
ES (1) ES2060033T3 (de)
GB (1) GB8909919D0 (de)
WO (1) WO1990013306A2 (de)

Families Citing this family (89)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5116964A (en) * 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
US6406697B1 (en) 1989-02-23 2002-06-18 Genentech, Inc. Hybrid immunoglobulins
US5225538A (en) * 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
DE69012950T2 (de) * 1989-10-13 1995-03-16 Takara Shuzo Co Antikrebsmittel.
US5610148A (en) * 1991-01-18 1997-03-11 University College London Macroscopically oriented cell adhesion protein for wound treatment
US5629287A (en) * 1991-01-18 1997-05-13 University College London Depot formulations
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
FR2719593B1 (fr) * 1994-05-06 1996-05-31 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur préparation et composition pharmaceutique les contenant.
US5641483A (en) * 1995-06-07 1997-06-24 Beaulieu; Andre Wound healing formulations containing human plasma fibronectin
US5877149A (en) 1995-06-07 1999-03-02 Beaulieu; Andre Deepithelialized skin diffusion cell system
US6528483B2 (en) 1995-06-07 2003-03-04 André Beaulieu Method of producing concentrated non-buffered solutions of fibronectin
US7112320B1 (en) 1995-06-07 2006-09-26 Andre Beaulieu Solid wound healing formulations containing fibronectin
JP3192067B2 (ja) * 1995-10-09 2001-07-23 科学技術振興事業団 ペプチドとコラーゲン収縮阻害剤
GB9526733D0 (en) 1995-12-30 1996-02-28 Delta Biotechnology Ltd Fusion proteins
US5922676A (en) * 1996-09-20 1999-07-13 The Burnham Institute Methods of inhibiting cancer by using superfibronectin
EP2206720A1 (de) 2000-04-12 2010-07-14 Human Genome Sciences, Inc. Albuminfusionsproteine
US6946134B1 (en) 2000-04-12 2005-09-20 Human Genome Sciences, Inc. Albumin fusion proteins
AU2001286688A1 (en) * 2000-08-25 2002-03-13 Human Genome Sciences, Inc. Tumor necrosis factor receptors 6alpha and 6beta
BR0116024A (pt) 2000-12-07 2005-12-13 Lilly Co Eli Proteìna de fusão heteróloga e uso da mesma
US7507413B2 (en) 2001-04-12 2009-03-24 Human Genome Sciences, Inc. Albumin fusion proteins
EP2261250B1 (de) 2001-12-21 2015-07-01 Human Genome Sciences, Inc. GCSF-Albumin Fusionsproteine
US20060002935A1 (en) 2002-06-28 2006-01-05 Domantis Limited Tumor Necrosis Factor Receptor 1 antagonists and methods of use therefor
GB0217033D0 (en) 2002-07-23 2002-08-28 Delta Biotechnology Ltd Gene and polypeptide sequences
CA2513213C (en) 2003-01-22 2013-07-30 Human Genome Sciences, Inc. Albumin fusion proteins
KR20070084069A (ko) 2004-10-08 2007-08-24 도만티스 리미티드 Ｔｎｆｒ1에 대한 단일 도메인 항체 및 이의 사용 방법
EA015860B1 (ru) 2005-10-13 2011-12-30 Хьюман Дженом Сайенсиз, Инк. Способы лечения аутоиммунных заболеваний при использовании антагониста нейтрокина-альфа
WO2007061896A1 (en) 2005-11-17 2007-05-31 Zogenix, Inc. Delivery of viscous formulations by needle-free injection
EP1816201A1 (de) 2006-02-06 2007-08-08 CSL Behring GmbH Modifizierter Koagulationsfaktor VIIa mit verbesserter 'half-life'-Stabiltät
US8268347B1 (en) 2006-10-24 2012-09-18 Aradigm Corporation Dual action, inhaled formulations providing both an immediate and sustained release profile
MX2009011870A (es) 2007-05-02 2009-11-12 Ambrx Inc Polipeptidos de interferon beta modificados y usos de los mismos.
CA2688433A1 (en) 2007-06-06 2008-12-11 Domantis Limited Methods for selecting protease resistant polypeptides
MX2010005317A (es) 2007-11-20 2010-06-02 Ambrx Inc Polipeptidos de insulina modificados y sus usos.
AU2009241847B2 (en) 2008-04-28 2014-07-10 Zogenix, Inc. Novel formulations for treatment of migraine
PL2274331T3 (pl) 2008-05-02 2014-04-30 Novartis Ag Ulepszone cząsteczki wiążące oparte na fibronektynie i ich zastosowanie
PT2318029T (pt) 2008-07-23 2018-01-10 Ambrx Inc Polipéptidos de g-csf bovino modificados e suas utilizações
CN102282168A (zh) 2008-11-18 2011-12-14 梅里麦克制药股份有限公司 人血清白蛋白接头以及其结合物
KR101740066B1 (ko) 2008-12-05 2017-05-25 글락소 그룹 리미티드 프로테아제 저항성 폴리펩티드를 선택하는 방법
CN102405236A (zh) 2009-02-19 2012-04-04 葛兰素集团有限公司 改进的抗-tnfr1多肽，抗体可变结构域和拮抗剂
WO2010138555A2 (en) 2009-05-26 2010-12-02 University Of Florida Research Foundation, Inc. Small peptide expression system in mammalian cells
EP2453920A2 (de) 2009-07-16 2012-05-23 Glaxo Group Limited Antagonisten, verwendung und verfahren zur teilweisen tnfr1-hemmung
BR112012010114A2 (pt) 2009-10-27 2017-08-08 Glaxo Group Ltd domínio variável único de imunoglobulina, ligante multiespecífico, antagonista, uso do antagonista, método para tratamento e/ou profilaxia de uma condição inflamatória em um paciente, ácido nucleico, vetor, e, célula hospedeira.
WO2011051466A1 (en) 2009-11-02 2011-05-05 Novartis Ag Anti-idiotypic fibronectin-based binding molecules and uses thereof
NZ600361A (en) 2009-12-21 2014-06-27 Ambrx Inc Modified bovine somatotropin polypeptides and their uses
JP2013515081A (ja) 2009-12-21 2013-05-02 アンブルックス，インコーポレイテッド 修飾されているブタのソマトトロピンポリペプチドおよびそれらの使用
WO2011092233A1 (en) 2010-01-29 2011-08-04 Novartis Ag Yeast mating to produce high-affinity combinations of fibronectin-based binders
EP4234698A3 (de) 2010-05-06 2023-11-08 Novartis AG Zusammensetzungen und verfahren zur verwendung von therapeutischen antikörpern gegen ldl-assoziiertes protein 6 (lrp6)
UA126265C2 (uk) 2010-07-09 2022-09-14 Байовератів Терапьютікс Інк. Поліпептид фактора іх і спосіб його застосування
MA34521B1 (fr) 2010-08-17 2013-09-02 Ambrx Inc Polypeptides de relaxine modifiés et leurs utilisations
NZ607337A (en) 2010-08-20 2015-06-26 Novartis Ag Antibodies for epidermal growth factor receptor 3 (her3)
EP2625264B1 (de) 2010-10-08 2022-12-07 Terumo BCT, Inc. Verfahren und systeme für züchtung und ernte von zellen in einem hohlfaser-bioreaktorsystem mit steuerungsbedingungen
US20130245233A1 (en) 2010-11-24 2013-09-19 Ming Lei Multispecific Molecules
EP2726502A1 (de) 2011-07-01 2014-05-07 Bayer Intellectual Property GmbH Relaxin-fusionspolypeptide und ihre verwendung
JP2014529293A (ja) 2011-07-08 2014-11-06 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ ＧｍｂＨ レラキシンを放出する融合タンパク質およびその使用
CN104039830A (zh) 2011-11-04 2014-09-10 诺华股份有限公司 低密度脂蛋白相关蛋白6(lrp6)-半寿期延长物构建体
AU2012349735B2 (en) 2011-12-05 2016-05-19 Novartis Ag Antibodies for epidermal growth factor receptor 3 (HER3)
KR20140103135A (ko) 2011-12-05 2014-08-25 노파르티스 아게 Her3의 도메인 ii에 대해 지시된 표피 성장 인자 수용체 3 (her3)에 대한 항체
WO2013170636A1 (zh) 2012-05-18 2013-11-21 爱德迪安（北京）生物技术有限公司 用于糖尿病治疗的蛋白、蛋白缀合物及其应用
US20150202287A1 (en) 2012-08-30 2015-07-23 Merrimack Pharmaceuticals, Inc. Combination therapies comprising anti-erbb3 agents
US10981961B2 (en) 2013-03-11 2021-04-20 University Of Florida Research Foundation, Incorporated Delivery of card protein as therapy for occular inflammation
EP2970479B1 (de) 2013-03-14 2019-04-24 Novartis AG Antikörper gegen notch 3
JP6633522B2 (ja) 2013-11-16 2020-01-22 テルモ ビーシーティー、インコーポレーテッド バイオリアクターにおける細胞増殖
CN112043835B (zh) 2013-12-06 2022-10-21 韩捷 用于含氮和羟基的药物的生物可逆引入基团
WO2015148704A1 (en) 2014-03-25 2015-10-01 Terumo Bct, Inc. Passive replacement of media
EP3157947A1 (de) 2014-06-23 2017-04-26 Novartis AG Hsa-gdf-15-fusionspolypeptid und verwendung davon
US20160090569A1 (en) 2014-09-26 2016-03-31 Terumo Bct, Inc. Scheduled Feed
KR20250078598A (ko) 2015-05-19 2025-06-02 예일 유니버시티 병리학적 석회화 병태를 치료하기 위한 조성물, 및 이의 사용 방법
WO2017004592A1 (en) 2015-07-02 2017-01-05 Terumo Bct, Inc. Cell growth with mechanical stimuli
CN108367053A (zh) 2015-12-22 2018-08-03 诺华股份有限公司 使用生长分化因子15(gdf-15)治疗或改善代谢性疾病的方法
WO2017125897A1 (en) 2016-01-21 2017-07-27 Novartis Ag Multispecific molecules targeting cll-1
JP7034949B2 (ja) 2016-05-25 2022-03-14 テルモ ビーシーティー、インコーポレーテッド 細胞の増殖
US11685883B2 (en) 2016-06-07 2023-06-27 Terumo Bct, Inc. Methods and systems for coating a cell growth surface
US11104874B2 (en) 2016-06-07 2021-08-31 Terumo Bct, Inc. Coating a bioreactor
US12234441B2 (en) 2017-03-31 2025-02-25 Terumo Bct, Inc. Cell expansion
CN117247899A (zh) 2017-03-31 2023-12-19 泰尔茂比司特公司 细胞扩增
US11624046B2 (en) 2017-03-31 2023-04-11 Terumo Bct, Inc. Cell expansion
UY38251A (es) 2018-06-01 2019-12-31 Novartis Ag Moléculas de unión contra bcma y usos de las mismas
EP3887393A1 (de) 2018-11-26 2021-10-06 Novartis AG Lpl-gpihbp1 fusionspolypeptide
US20220098252A1 (en) 2019-01-25 2022-03-31 Ospedale San Raffaele S.R.L. Inhibitor of dux4 and uses thereof
EP3972993A1 (de) 2019-05-21 2022-03-30 Novartis AG Variante cd58-domänen und deren verwendungen
PE20220568A1 (es) 2019-05-21 2022-04-20 Novartis Ag Moleculas de union a cd19 y usos de las mismas
CN114341195B (zh) 2019-09-06 2025-04-25 诺华股份有限公司 治疗性融合蛋白
US20240025993A1 (en) 2020-11-06 2024-01-25 Novartis Ag Cd19 binding molecules and uses thereof
GB2619893A (en) 2021-03-23 2023-12-20 Terumo Bct Inc Cell capture and expansion
US12152699B2 (en) 2022-02-28 2024-11-26 Terumo Bct, Inc. Multiple-tube pinch valve assembly
US20230357381A1 (en) 2022-04-26 2023-11-09 Novartis Ag Multispecific antibodies targeting il-13 and il-18
USD1099116S1 (en) 2022-09-01 2025-10-21 Terumo Bct, Inc. Display screen or portion thereof with a graphical user interface for displaying cell culture process steps and measurements of an associated bioreactor device
EP4389762A1 (de) 2022-12-23 2024-06-26 Ospedale San Raffaele S.r.l. Inhibitoren der dux4-aktivität und ihre therapeutische verwendung.
CN116574173B (zh) * 2023-06-25 2026-04-17 浙江诸暨聚源生物技术有限公司 蛋白稳定性增强的重组人源纤连蛋白突变体及其表达菌株
WO2026058155A1 (en) 2024-09-11 2026-03-19 Novartis Ag Antibodies targeting il-31

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8516421D0 (en) * 1985-06-28 1985-07-31 Biotechnology Interface Ltd Fibronectins
SE459586B (sv) * 1987-09-14 1989-07-17 Mta Szegedi Biolog Koezponti Strukturgen som kodar foer autentiskt humant serum albumin och foerfarande foer dess framstaellning
GB8725529D0 (en) * 1987-10-30 1987-12-02 Delta Biotechnology Ltd Polypeptides
AU2719088A (en) * 1987-11-09 1989-06-01 Chiron Ophthalmics Inc. Wound healing composition and method

Also Published As

Publication number Publication date
EP0399666B1 (de) 1993-07-28
EP0399666A1 (de) 1990-11-28
DE69002395D1 (de) 1993-09-02
WO1990013306A3 (en) 1991-05-02
ATE92107T1 (de) 1993-08-15
EP0407008A3 (en) 1991-07-17
ES2060033T3 (es) 1994-11-16
GB8909919D0 (en) 1989-06-14
DE69002395T2 (de) 1993-11-25
WO1990013306A2 (en) 1990-11-15
EP0407008A2 (de) 1991-01-09

Similar Documents

Publication Publication Date Title
DK0399666T3 (da) Fusionsproteiner indeholdende N-terminalfragmenter af human serumalbumin
ES2070919T3 (es) Separacion cromatografica de las proteinas del plasma, principalmente del factor viii, del factor de willebrand de la fibronectina y del fibrinogeno.
EP0751992A4 (de) Vaskularer endothelialer wachstumsfaktor 2
DE3874798D1 (de) Therapeutisches proteinagens in form von aerosol.
DE69227041D1 (de) Expression und reinigung von rekombinantem, löslichem gewebefaktor
DK0502956T3 (da) Fremstilling af en rekombinant human interleukin-1-inhibitor.
ATE177754T1 (de) Fragmente von prion proteinen.
ATE178907T1 (de) Rezeptorbindende region des diphtherietoxius
IT1229484B (it) Virus ricombinante delle malattie esantematiche dei vertebrati.
ES2129487T3 (es) Peptidos sinteticos, anticuerpos dirigidos contra ellos y su utilizacion.
ES2075155T3 (es) Separacion enzimatica de una secuencia de una proteina con amino terminal.
PT737207E (pt) Inibidores de plasmina humana derivados de dominios kunitz
ATE295414T1 (de) Menschliche ctla-8 und verwendung von ctla-8 ähnlichen proteinen
DE69309044D1 (de) Behandlung von asthma
NO923737D0 (no) Forbedret vevs-lim fremstilt ved anvendelse av kryopresipitat
ATE220688T1 (de) Tumor-zerstörende effekte von enterotoxinen und verwandten verbindungen
ATE95847T1 (de) Koagulationsverfahren fuer filamente.
FI953565A7 (fi) Uusi antikoagulanttikofaktoriaktiivisuus
DE68921229D1 (de) Prozess zur Behandlung von unlöslichem heterogenem Fusionsprotein.
ATE205529T1 (de) Reninaktive substanz enthaltend humanes prorenin und antikörper gegen das prorenin profragment
ES2101694T3 (es) Expresion de edulcorantes proteinicos en levadura.
DE69010750D1 (de) Antikörper gegen Fibrin, immunogene Peptide für die Herstellung dieser Antikörper, Verfahren zur Bestimmung von Fibrin und pharmazeutische Zubereitungen auf der Basis dieser Antikörper.
SE9000793D0 (sv) Sdk-peptider,foerfarande foer framstaellning daerav och terapeutiska kompositioner innehaallande dem
EP0326013A3 (de) Von menschlichem alpha-2-Plasmin-Inhibitor abgeleitete neue Proteine oder Proteine, die diesen ähnlich sind
FR2646607B1 (fr) Anticorps monoclonaux anti-b2 microglobuline